Qing Yun Moyeam tea leaves — subject of thousands of peer-reviewed scientific studies on Myricetin
64+ Peer-Reviewed Citations

Medical Sources

Every claim Pureami Tea Company makes is grounded in published, peer-reviewed medical literature. Below are the sources — all available free at PubMed.com.

Our Commitment to Transparency

The three names — Myricetin, DiHydroMyricetin, and Ampelopsin — all refer to the same flavonol. Search any of them on PubMed.com and you will find a substantial body of evidence. Qing Yun Moyeam produces this compound at 30–40% by plant weight, versus 3–6% for ordinary grades.

We do not cherry-pick studies. We have never made a claim not supported by the published literature. All citations below link directly to their source on PubMed or the original journal.

Medical research laboratory — Myricetin and Moyeam tea studies published on PubMed
Scientific journal alongside Qing Yun Moyeam tea — peer-reviewed research on flavonols

Qing Yun Moyeam

Ampelopsis Grossedentata — Myricetin / DiHydroMyricetin / Ampelopsin

2 studies

Triple Negative Breast Cancer

19.
Myricetin-induced apoptosis of triple-negative breast cancer cells is mediated by iron-dependent generation of reactive oxygen species from hydrogen peroxide

PubMed

Myricetin selectively triggered cancer cell death in triple-negative breast cancer — one of the most difficult-to-treat forms — through a targeted oxidative mechanism.

20.
Myricetin suppresses breast cancer metastasis through down-regulating the activity of matrix metalloproteinase (MMP)-2/9

PubMed

Myricetin was shown to reduce the spread (metastasis) of breast cancer cells by blocking the enzymes that allow tumors to invade surrounding tissue.

SH003 Blend

Astragalus membranaceus · Angelica gigas · Trichosanthes kirilowii

2 studies

Triple Negative Breast Cancer

61.
Synergistic effect of SH003 and doxorubicin in triple-negative breast cancer

PubMed

When combined with the chemotherapy drug doxorubicin, SH003 produced a synergistic effect — meaning the combination was significantly more powerful than either treatment alone against triple-negative breast cancer.

62.
SH003 selectively induces p73-dependent apoptosis in triple-negative breast cancer cells

PubMed

SH003 selectively triggered programmed cell death specifically in triple-negative breast cancer cells — the most aggressive and treatment-resistant subtype — while sparing healthy cells.

Disclaimer: The research cited above is provided for educational purposes only and reflects the findings of independent researchers. Pureami Tea Company does not claim that Moyeam diagnoses, treats, cures, or prevents any disease. These statements have not been evaluated by the FDA. Consult your healthcare provider before making any changes to your diet or supplement regimen.